Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2341547 | 0.85 | TACR1 (0.59) | TACR1MEN1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL5340479 | 0.83 | TACR1 (0.54) | TACR1MEN1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL660541 | 0.82 | MMP13 (0.70) | MEN1KMT2AMTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL18183526 | 0.81 | SMN1; SMN2 (0.70) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL6289037 | 0.81 | TACR1 (0.60) | TACR1MEN1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL13306937 | 0.81 | TACR1 (0.52) | TACR1MEN1KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL14672755 | 0.81 | TACR1 (0.60) | TACR1MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL6289038 | 0.81 | TACR1 (0.60) | TACR1MEN1KMT2ASMN1; SMN2HIF1A | |
| Hydrochloric Acid SCHEMBL29194804 | 0.81 | MMP13 (0.68) | MEN1KMT2AMTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL11210850 | 0.81 | KMT2A (0.57) | KMT2ASMN1; SMN2HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1265897-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| CN-1344256-A | (Hetero) aryl-bicyclic heteroaryl derivatives, their prepn. and their use as protease inhibitors | AXYS PHARM INC (US) | 2002-04-10 | — | — | CN | disclosed |
| EP-1140859-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001070743-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | TFPI, HABP2, PLAT | TACR1 3257/4885MEN1 2391/4885KMT2A 1317/4885 |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | TFPI, SERPINE1, HABP2 | TACR1 2210/4885MEN1 684/4885KMT2A 2549/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | TACR1 3817/4885MEN1 3032/4885KMT2A 1449/4885 |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | TFPI, SERPINE1, HABP2 | TACR1 3345/4885MEN1 2151/4885KMT2A 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.